<?xml version="1.0" encoding="UTF-8"?>
<p id="para0020">The drug discovery strategy bears the brunt of the COVID-19 outbreak is the test of existing broad-spectrum antiviral agents that have been harnessed to cure other viral infections via utilizing standard tests for measuring the effects of drugs on the cytopathy, virus production along with plaque generation in live and pseudotyped CoVs 
 <xref rid="bib0067" ref-type="bibr">[67]</xref>. Drug discovery utilizing this method encompass interferon α, interferon β, interferon γ, arbidol, ribavirin, along with cyclophilin inhibitors 
 <xref rid="bib0065" ref-type="bibr">[65</xref>,
 <xref rid="bib0066" ref-type="bibr">66</xref>,
 <xref rid="bib0068" ref-type="bibr">68]</xref>. These drugs possess the distinct preponderance of easy access to known pharmacokinetic and pharmacodynamic features, dose regimens, and adverse effects 
 <xref rid="bib0069" ref-type="bibr">[69]</xref>. Nevertheless, they have no specific anti-SARS-CoV-2 effect and may be correlated with severe untoward effects.
</p>
